Abstract
OBJECTIVE: Offspring of type 2 diabetics have an increased risk of dyslipidemia, glucose intolerance and obesity. The aim of this study was to assess the lipid levels in the offspring of diabetics with normal glucose tolerance and normal body weight. DESIGN: Normal weight offspring of patients with type 2 diabetes mellitus (DM) who had normal glucose tolerance, and healthy gender matched controls of comparable age without a family history of diabetes mellitus, were the subjects of this study. Lipid profiles were determined in cases and controls. RESULTS: The study included 114 subjects (64 males and 50 females) in each group, aged (mean±SD) 24.0±7.9 in cases and 24.1±8.0 years in controls. The body mass index (BMI) was 20.8±3.0 and 20.2±3.1 kg/m2 in cases and controls, respectively. Serum total cholesterol, triglycerides, plasma glucose, fasting insulin, C-peptide and proinsulin levels were comparable in cases and controls. Serum high density lipoprotein (HDL) cholesterol was lower (p <0.001), whilst the serum triglyceride/HDL ratio, low density lipoprotein (LDL) cholesterol and area under the curve for insulin and proinsulin during an oral glucose tolerance test were higher in cases compared to controls. HDL cholesterol showed no significant correlation with plasma glucose, insulin or proinsulin. CONCLUSION: Plasma HDL cholesterol is low among normal weight, normoglycemic offspring of subjects with type 2 diabetes mellitus. The implications of this finding are not apparent.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C, 2002 World Heart Day 2002: The international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106: 1602–1605.
Ueshima H, Sekikawa A, Miura K, et al, 2008 Cardiovascular disease and risk factors in Asia: a selected review. Circulation 118: 2702–2709.
Eckel RH, Kahn R, Robertson RM, Rizza RA, 2006 Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 113: 2943–2946.
Diabetes drafting group, 1985 Prevalence of small vessel and large vessel disease in diabetic persons from 14 centers. The World Health Organization multinational study of vascular disease in diabetics. Diabetologia 28: Suppl 1: 615–640.
Ganda OP, 1980 Pathogenesis of macrovascular disease in the human diabetic. Diabetes 29: 931–942.
Singleton JR, Smith AG, Russell JW, Feldman EL, 2003 Microvascular complications of impaired glucose tolerance. Diabetes 52: 2867–2873.
Shaw JT, Purdie DM, Neil HA, Levy JC, Turner RC, 1999 The relative risks of hyperglycemia, obesity and dyslipidemia in the relatives of patients of type II diabetes mellitus. Diabetologia 42: 24–27.
Pontiroli AE, Monti LD, Pizzini A, Piatti P, 2000 Familial clustering of arterial blood pressure, HDL-cholesterol, and proinsulin but not insulin resistance and microalbuminuria in siblings of patients with type 2 diabetes. Diabetes Care 23: 1359–1364.
Eckel RH, Grundy SM, Zimmet PZ, 2005 The Metabolic syndrome. Lancet 365: 1415–1428.
Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK, 1990 Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263: 2893–2898.
Chathurvedi D, Khadgawat R, Kulshrestha B, et al, 2009 Type 2 diabetes increases the risk for obesity among subsequent generations. Diabetes Technol Ther 11: 393–398.
Jouret B, Ahluwalia N, Cristini C, et al, 2007, Factors associated with overweight in preschool-age children in southwestern France. Am J Clin Nutr 85: 1643–1649.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH, 2000 Establishing a standard definition for child overweight and obesity worldwide: International survey. BMJ 320: 1240–1243.
Bowsher RR, Wolny JD, Frank BH, 1992 Rapid and sensitive radioimmunoassay assay for the measurement of proinsulin in human serum. Diabetes 41: 1084–1090.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2003 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26: Suppl 1: 5–20.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel (III), 2002 Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421.
Kavey RE, Daniels SR, Lauer RM, et al, American Heart association, 2003 American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107: 1562–1566.
Tai MM, 1994 A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17: 152–154.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
Matsuda M, DeFronzo RA, 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with euglycemic insulin clamp. Diabetes Care 22: 1462–1470.
Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B, 2008 Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16: 1901–1907.
Tuomilehto J, Lindström J, Eriksson JG, et al, 2001 Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.
Buchanan TA, Xiang AH, Peters RK, et al, 2002 Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796–2803.
Chiasson JL, Josse RG, Gomis R, et al, STOP-NIDDM Trial Research Group, 2002 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077.
Buchanan TA, 2007 (How) can we prevent type 2 diabetes? Diabetes 56: 1502–1507.
Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK, Ferrannini E, 1989 Parental history of diabetes is associated with increased cardiovascular risk factors. Arteriosclerosis 9: 928–933.
Choo KE, Lau KB, Davis WA, Chew PH, Jenkins AJ, Davis TM, 2007 Cardiovascular risk factors in prepu-bertal Malays. Effects of diabetic parentage. Diabetes Res Clin Pract 76: 119–125.
Tan JT, Tan LS, Chia KS, Chew SK, Tai ES, 2008 A family history of type 2 diabetes is associated with glucose intolerance and obesity-related traits with evidence of excess maternal transmission for obesity-related traits in a South East Asian population. Diabetes Res Clin Pract 82: 268–275.
Anjana RM, Lakshminarayanan S, Deepa M, Farooq S, Pradeepa R, Mohan V, 2009 Parental history of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular risk factors in Asian Indian adolescents. Metabolism 58: 344–350.
Psyrogiannis A, Habeos I, Kyriazopoulou V, 2003 Insulin sensitivity and Lp(alpha) concentrations in normoglyce-mic offspring of type 2 diabetic parents. Lipids Health Dis 2: 8.
Groop L, Forsblom C, Lehtovirta M, et al, 1996 Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45: 1585–1593.
Tian H, Han L, Ren Y, Li X, Liang J, 2003 Lipoprotein(a) level and lipids in type 2 diabetic patients and their normoglycemic first-degree relatives in type 2 diabetic pedigrees. Diabetes Res Clin Pract 59: 63–69.
Abbott WG, Lillioja S, Young AA, et al, 1987 Relationships between plasma lipoprotein concentration and insulin action in an obese hyperinsulinemic population. Diabetes 36: 897–904.
Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM, 1993 Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92: 141–146.
Selby JV, Austin MA, Newman B, et al, 1993 LDL subclass phenotypes and the insulin resistance syndrome in woman. Circulation 88: 381–387.
Garg A, 1996 Insulin resistance in the pathogenesis of Dyslipidemia. Diabetes Care 19: 387–389.
Wilson PW, McGee DL, Kannel WB, 1981 Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: The Framingham Study. Am J Epidemiol 114: 697–704.
Von Eckardstein A, Schulte H, Assmann G, 2000 Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab 85: 3101–3108.
Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM, 2010. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in woman. Diabetes 59: 1153–1160.
Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY, 1995 Proinsulin as marker for the development of NIDDM in Japanese American men. Diabetes 44: 173–179.
Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B, 2000 HDL-cholesterol as a marker of coronary heart disease risk: the Quebec Cardiovascular Study. Atherosclerosis 153: 263–272.
Assmann G, Schulte H, von Eckardstein A, Huang Y, 1996 High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124: Suppl: 11–20.
Ferns G, Keti V, 2008 HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem 45: 122–128.
Roehrich ME, Mooser V, Lenain V, et al, 2003 Insulin-secreting beta-cell dysfunction induced by human lipo-proteins. J Biol Chem 278: 18368–18375.
Rutti S, Ehses JA, Sibler RA, et al, 2009 A low and high density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta cells. Endocrinology 150: 4521–4530.
Tenenbaum A, Motro M, Fisman EZ, et al, 2004 Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197–2202.
Drew BG, Duffy SJ, Formosa MF, et al, 2009 High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119: 2103–2111.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Praveen, E.P., Kulshreshtha, B., Khurana, M.L. et al. Low HDL-cholesterol among normal weight, normoglycemic offspring of individuals with type 2 diabetes mellitus. Hormones 10, 57–66 (2011). https://doi.org/10.14310/horm.2002.1293
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1293